Mechanistic Insights into Hsp104 Potentiation by Torrente, Mariana P. et al.
Mechanistic Insights into Hsp104 Potentiation*
Received for publication,December 1, 2015, and in revised form, January 4, 2016 Published, JBC Papers in Press, January 8, 2016, DOI 10.1074/jbc.M115.707976
Mariana P. Torrente‡1, Edward Chuang‡§2, MeganM. Noll‡, Meredith E. Jackrel‡3, Michelle S. Go‡4,
and James Shorter‡§5
From the ‡Department of Biochemistry and Biophysics and the §Pharmacology Graduate Group, Perelman School of Medicine,
University of Pennsylvania, Philadelphia, Pennsylvania 19104
Potentiated variants of Hsp104, a protein disaggregase from
yeast, candissolve protein aggregates connected to neurodegen-
erative diseases such as Parkinson disease and amyotrophic lat-
eral sclerosis. However, the mechanisms underlying Hsp104
potentiation remain incompletely defined. Here, we establish
that 2–3 subunits of the Hsp104 hexamer must bear an A503V
potentiatingmutation to elicit enhanceddisaggregase activity in
the absence ofHsp70.We also define theATPase and substrate-
bindingmodalities needed for potentiated Hsp104A503V activ-
ity in vitro and in vivo. Hsp104A503V disaggregase activity is
strongly inhibited by the Y257A mutation that disrupts sub-
strate binding to the nucleotide-binding domain 1 (NBD1) pore
loop and is abolished by the Y662A mutation that disrupts sub-
stratebinding to theNBD2pore loop. Intriguingly,Hsp104A503V dis-
aggregase activity responds to mixtures of ATP and adenosine
5-(-thio)-triphosphate (a slowly hydrolyzable ATP analogue)
differently from Hsp104. Indeed, an altered pattern of ATP hy-
drolysis and altered allosteric signaling between NBD1 and
NBD2 are likely critical for potentiation. Hsp104A503V variants
bearing inactivating Walker A or Walker B mutations in both
NBDs are inoperative. Unexpectedly, however, Hsp104A503V retains
potentiated activity upon introduction of sensor-1 mutations
that reduce ATP hydrolysis at NBD1 (T317A) or NBD2 (N728A).
Hsp104T317A/A503V and Hsp104A503V/N728A rescue TDP-43 (TAR
DNA-binding protein 43), FUS (fused in sarcoma), and -synuclein
toxicity inyeast.Thus,Hsp104A503Vdisplays amore robust activity
that is unperturbed by sensor-1 mutations that greatly reduce
Hsp104 activity in vivo. Indeed, ATPase activity atNBD1orNBD2
is sufficient for Hsp104 potentiation. Our findings will empower
designof ameliorated therapeutic disaggregases for variousneuro-
degenerative diseases.
Protein misfolding and aggregation are associated with a
wide variety of diseases, ranging from type II diabetes (1, 2) to
neurodegenerative diseases, such as fatal familial insomnia (3,
4), Parkinson disease, and amyotrophic lateral sclerosis (ALS)
(5–7). In Parkinson disease patients, -synuclein (-syn)6
forms toxic soluble oligomers as well as amyloid structures that
accumulate in Lewy bodies and contribute to the death of dop-
aminergic neurons (8–12). Similarly, toxic soluble oligomers
and cytoplasmic inclusions of TDP-43 or FUS are associated
with ALS and frontotemporal dementia (13–20). These mis-
folded protein conformers are recalcitrant and represent a
colossal roadblock in the treatment of these diseases.
Hsp104 is a 102-kDa AAAATPase (21) from Saccharomy-
ces cerevisiae capable of dissolving disordered protein aggre-
gates as well as dismantling amyloid fibrils and toxic soluble
oligomers (22–33). It assembles into a homohexameric barrel
structure with a central channel (34–39). Hsp104 processes
protein aggregates by directly translocating substrates either
partially or completely through this channel (35, 36, 40–46).
Hsp104 encompasses an N-terminal domain, two nucleotide-
binding domains (NBD1 and NBD2), a coiled-coil middle
domain (MD), and a C-terminal domain important for oligo-
merization (Fig. 1A) (47). Both NBDs contain Walker A and
Walker B motifs that are critical for nucleotide binding and
hydrolysis, respectively (48). ATP hydrolysis takes place pri-
marily at NBD1, whereas NBD2 has a nucleotide-dependent
oligomerization function (29, 34, 49–52).
Remarkably, Hsp104 can remodel amyloid substrates alone,
without the aid of any other chaperones (22, 24, 26, 31, 33, 45,
53–56). However, to disaggregate amorphous protein aggre-
gates, Hsp104 usually needs to collaborate with the Hsp110,
Hsp70, and Hsp40 chaperone system (23, 26, 30, 32, 57). More-
over, small heat shock proteins such as Hsp26 can enhance
disaggregase activity further (30, 57–59). In vitro, mixtures of
ATP and ATPS (a slowly hydrolyzable ATP analogue) enable
Hsp104 to dissolve amorphous aggregates in the absence of
Hsp70 and Hsp40 (26, 35, 60, 61).
Wild-type (WT) Hsp104 can resolve -syn oligomers and
fibrils, but very high Hsp104 concentrations are required (26,
31, 32). Hsp104 has limited disaggregase activity against
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TDP-43 and FUS fibrils (62, 63). Recently, we have engineered
potentiated Hsp104 variants that mitigate TDP-43, FUS, and
-synmisfolding (62–67). Missense mutations at disparate but
specific positions in the MD or the small domain of NBD1
(immediately C-terminal to the MD) resulted in potentiated
Hsp104 variants (62, 67). Potentiating mutations in the MD
obviate any absolute requirement for Hsp70 in disaggregation
of amorphous aggregates and typically (under physiological salt
conditions) enhance Hsp104 ATPase activity (62, 67). Potenti-
atedHsp104 variants also display accelerated substrate translo-
cation, enhanced unfoldase activity, and enhanced amyloid-re-
modeling activity (45, 62). They can also recognize shorter
unfolded tracts in client proteins compared with Hsp104 (63).
Hsp104A503V has been previously established as a potentiated
Hsp104 variant able to ameliorate the toxicity arising from the
aggregation of WT or disease-linked forms of -syn, FUS, and
TDP-43 in yeast (62, 63). Hsp104A503V hexamers also display
enhanced plasticity and aremore resistant to defective subunits
than Hsp104 (62). However, Hsp104A503V is more sensitive
than Hsp104 to suramin, a small molecule inhibitor of Hsp104
ATPase activity (68). Interestingly, two potentiated Hsp104
variants, Hsp104A503S and Hsp104Y257F/A503V/Y662F, rescue
neurodegeneration in the metazoan nervous system and hold
promise as possible treatments for neurodegenerative disease
(62, 66).
Despite these advances, the molecular mechanisms underly-
ing the potentiation of Hsp104 are incompletely understood.
TheN-terminal domain ofHsp104 is critical forHsp104 poten-
tiation, as is motif 1 (helix 1 and a portion of helix 2) of the MD
(35, 47, 67). Thus, deletion of these large regions precludes
potentiation (35, 67). However, beyond these domain require-
ments, little else is known. Here, we explore how many A503V
subunits are needed per hexamer to enable enhanced activity.
We also determine which Hsp104 ATPase and substrate-bind-
ing modalities are important for potentiation both in vitro and
in vivo. The mechanistic insights gleaned from our studies will
enable further development of potentiated Hsp104 variants as
therapeutics for various neurodegenerative diseases.
Experimental Procedures
Materials—All chemicals were purchased from Sigma-Al-
drich unless otherwise specified. Creatine kinase was pur-
chased from Roche Applied Science. Firefly luciferase was pur-
chased from Sigma-Aldrich. Luciferase assay reagent was
purchased from Promega (Madison, WI). Hsp70 (Hsp72) and
Hsp40 Hdj1 were purchased from Enzo Life Sciences (Farm-
ingdale, NY).
Protein Expression and Purification—Sixteen Hsp104 variants:
Hsp104, Hsp104Y257A, Hsp104T317A, Hsp104A503V, Hsp104Y662A,
Hsp104N728A, Hsp104K218T/K620T, Hsp104E285Q/E687Q,
Hsp104Y257A/Y662A, Hsp104Y257A/A503V, Hsp104T317A/A503V,
Hsp104Y662A/A503V, Hsp104N728A/A503V, Hsp104K218T/A503V/K620T,
Hsp104E285Q/A503V/E687Q, and Hsp104Y257A/A503V/Y662A were
purified as reported previously (52, 61, 69). Briefly, untagged
Hsp104 was transformed into BL21-DE3 RIL cells (Agilent
Technologies, Santa Clara, CA). Expression was induced at an
A600 of 0.4–0.6 with 1 mM isopropyl 1-thio--D-galactopyra-
noside for 15–18 h at 15 °C. Cells were harvested via centrifu-
gation (4,000 rpm, 4 °C, 20min), resuspended in lysis buffer (50
mM Tris-HCl, pH 8.0, 10 mM MgCl2, 2.5% glycerol (w/v), 2 mM
-mercaptoethanol (Bio-Rad), 5 M pepstatin A, and 1 Mini-
complete EDTA free protease tablet per 50 ml (Roche Applied
Science), and lysed by sonication. Cell debris was removed via
centrifugation at 16,000 rpm at 4 °C for 20 min. The superna-
tant was applied to Affi-Gel Blue resin (Bio-Rad). Supernatant
and resin were rotated at 4 °C for 4 h. Resin was then washed
with wash buffer (50 mM Tris-HCl, pH 8.0, 10 mM MgCl2, 100
mM KCl, 2.5% glycerol (w/v), 2 mM -mercaptoethanol).
Hsp104 was eluted with high salt buffer (wash buffer plus 1 M
KCl). Hsp104 was then further purified by ResourceQ anion
exchange chromatography using running bufferQ (20mMTris-
HCl, pH 8.0, 0.5 mM EDTA, 5 mM MgCl2, 50 mM NaCl) and
eluted with a linear gradient of buffer Q (20mMTris-HCl, pH
8.0, 0.5 mM EDTA, 5 mM MgCl2, 1 M NaCl). Eluate was
exchanged into storage buffer (40 mM HEPES-KOH, pH 7.4,
150 mM KCl, 20 mM MgCl2, 10% glycerol, 1 mM DTT), snap-
frozen, and stored at 80 °C. High salt storage buffer (40 mM
HEPES-KOH, pH 7.4, 500mMKCl, 20mMMgCl2, 10% glycerol,
1 mM DTT) was used for storage of Hsp104A503V and all other
Hsp104 variants containing this mutation.
ATPase Assay—WT or mutant Hsp104 (0.25 M monomer)
in ATPase buffer (20 mM HEPES-KOH, pH 7.4, 20 mM NaCl,
and 10 mM MgCl2) was incubated for 10 min at 25 °C in the
presence of ATP (1 mM) as noted (52). ATPase activity was
assessed by the release of inorganic phosphate determined by
using a malachite green phosphate detection kit (Innova Bio-
sciences, Cambridge, UK).
Luciferase Disaggregation Assays—Luciferase reactivation
was performed as described (23, 61). To assemble aggregates,
firefly luciferase (50 M) in luciferase refolding buffer (25 mM
HEPES-KOH, pH 7.4, 150 mM potassium acetate, 10 mM mag-
nesium acetate, 10 mM DTT) with 6 M urea was incubated at
30 °C for 20 min. Luciferase was then rapidly diluted 100-fold
into luciferase refolding buffer, divided into 100-l aliquots,
snap-frozen in liquid N2, and stored at80 °C. For reactivation
assays, aggregated luciferase (50 nM) was incubated with
Hsp104 (1 M hexamer) plus 5 mM ATP (or the indicated
ATPS andATP ratio amounting to the same total) and anATP
regeneration system (10 mM creatine phosphate, 0.5 M crea-
tine kinase (Roche Applied Science), 0.1mMATP) for 90min at
25 °C. For some assays, Hsp70 (1 M) and Hsp40 (1 M; Enzo
Life Sciences) were added. Luciferase activity was assessed by
luminescence measured on a Safire2 microplate reader (Tecan,
Ma¨nnedorf, Switzerland).
Subunit Doping Assay—Hsp104 was mixed with Hsp104A503V in
varying ratios to give a total concentration of 0.167 MHsp104
hexamer, and the luciferase reactivation experiments were per-
formed as described above. Hsp70 and Hsp40 were omitted for
these experiments such that WT Hsp104 was inactive. Thus,
under these conditions, we are certain that if the number of WT
subunits per hexamer exceeds five, then the hexamer is inac-
tive. We employed the approach of Reinstein and colleagues
(70) to simulate the distribution of Hsp104 and Hsp104A503V
subunits within a given population of Hsp104 hexamers as
described (26, 61, 62, 70). Thus, we employed the binomial
distribution,
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P x   nx px1  pn  x (Eq. 1)
where P is the probability that a hexamer (therefore, n  6)
contains x WT subunits, and p is the probability that a WT
subunit is incorporated (26, 61, 62, 70). Experiments demon-
strated thatWT and A503V subunits have a similar probability
of being incorporated into a hexamer (26, 62). Consequently, p
is calculated as the molar ratio of WT and A503V protein
present.
p 
Hsp104
Hsp104 Hsp104A503V
(Eq. 2)
Therefore, for any specified percentage of WT subunits, the
probability distribution of Hsp104A503V hexamers containing
zero, one, two, three, four, five, or six WT subunits can be
derived (Fig. 1B) (26, 61, 62, 70). Activity versus p plots could
then be generated, assuming each A503V subunit makes an
equal contribution to the total activity (one-sixth per subunit)
(Fig. 1C) (26, 61, 62, 70). Consequently, if subunits within the
Hsp104A503V hexamer operate independently, then activity
should decline in a linear manner upon incorporation of WT
subunits (26, 61, 62, 70). Conversely, if subunits are coupled,
then a specific number of WT subunits will be sufficient to
eliminate activity (26, 61, 62, 70). Thus, zero activity is assigned
to hexamers that are in breach of a specific threshold number of
WT subunits (26, 61, 62, 70). In this way, we can generate activ-
ity versus p plots if we assume that 1 or more, 2 or more, 3 or
more, 4 or more, or 5 or more WT subunits are required to
eliminate activity (26, 61, 62, 70).
To further model the observed inhibitory effect of WT
Hsp104 subunits on Hsp104A503V activity, we employed the
binomial distribution as above but imposed an additional rule
whereby WT subunits repress the activity of adjacent A503V
subunits by a factor of r (26, 35, 62, 71). Thus, we scored each
subunit-subunit interface of every possible heterohexamer in
each possible configuration as follows: interfaceswere scored as
1/6 if at an A503V:A503V junction, r/6 if at an A503V:WT
junction, or 0 if at aWT:WT junction (26, 62). Activitywas then
normalized to the predicted heterohexamer population as
defined by the binomial distribution above (Fig. 1B) (26, 59).
Yeast Strains, Media, and Plasmids—All yeasts wereW303a-
hsp104 (MATa, can1-100, his3-11,15, leu2-3,112, trp1-1,
ura3-1, ade2-1) (72). Yeasts were grown in synthetic medium
lacking the appropriate components. Mediumwas supplemented
with 2%glucose, raffinose, or galactose. Vectors encodingTDP-43,
FUS, and -syn (pAG303GAL-TDP-43, pAG303GAL-FUS, and
pAG303GAL--syn-GFP, respectively) were from A. Gitler
(73–75). pRS416GAL-Hsp104 variants have been described
previously (62). Hsp104 mutations were generated using
QuikChange site-directed mutagenesis (Agilent Technologies,
Santa Clara, CA) and confirmed by DNA sequencing.
Yeast Transformation and Spotting Assays—Yeast were
transformed according to standard protocols using polyethyl-
ene glycol and lithium acetate (76). For the spotting assays,
yeasts were grown to saturation overnight in raffinose supple-
mented dropout medium at 30 °C. Cultures were serially
diluted 5-fold and spotted in duplicate onto synthetic dropout
medium containing glucose or galactose. Plates were analyzed
after growth for 2–3 days at 30 °C.
Western Blotting—Yeasts were grown and induced in galac-
tose-containing medium for 5 h (TDP-43 and FUS) or 8 h
(-syn-GFP). Cultures were normalized to an optical density of
0.6; 6 ml of cells were then harvested and treated with 0.2 M
NaOH for 5min at room temperature. The resulting cell pellets
were resuspended in 100 l of 1	 SDS sample buffer and
boiled. Cell lysates were separated using SDS-PAGE (4–20%
gradient; Bio-Rad) and then transferred to a PVDF membrane
(EMD Millipore, Billerica, MA). Membranes were blocked
using LI-COR blocking buffer for 1 h at room temperature.
Primary antibody incubations were performed at 4 °C over-
night. Antibodies used were as follows: rabbit anti-GFP poly-
clonal (Sigma-Aldrich, catalog no. G1544), rabbit anti-TDP-43
polyclonal (Proteintech (Chicago, IL), catalog no. 10782-2-AP),
rabbit anti-FUS polyclonal (Bethyl Laboratories (Montgomery,
TX), catalog no. A300-302A), rabbit anti-Hsp104 polyclonal
(Enzo Life Sciences, catalog no. ADI-SPA-1040-F), and mouse
anti-3-phosphoglycerate kinase monoclonal (Novex (Freder-
ick, MD), catalog no. 459250). Blots were processed using goat
anti-mouse and anti-rabbit secondary antibodies from LI-COR
Biosciences (Lincoln, NE) and imaged using an Odyssey Fc
Imaging system (LI-COR Biosciences).
Results
Hsp104 Hexamers Must Contain 2–3 A503V Subunits for
Enhanced Disaggregase Activity—To gain insight into themech-
anism of Hsp104 potentiation, we focused on Hsp104A503V (Fig.
1A), which is among the strongest suppressors of-syn, FUS, and
TDP-43 toxicity in yeast (62, 63, 67). First, we explored the
effects of WT Hsp104 subunits on the disaggregase activity of
Hsp104A503V hexamers. To do so, we exploited the strict
requirement of Hsp104 for Hsp70 and Hsp40 to reactivate
luciferase trapped in disordered aggregates in the presence of
ATP (23, 26). In the absence of Hsp70 andHsp40, Hsp104 reac-
tivation activity was abolished (Fig. 1C) (23, 26). By contrast,
Hsp104A503V displayed robust luciferase reactivation activity in
the absence of Hsp70 and Hsp40 (Fig. 1C) (62). Thus, under
these conditions, we are certain that if the number of WT sub-
units per Hsp104 hexamer exceeds five, then the hexamer is
inactive. To determine howmanyA503V subunits per hexamer
are required to elicit disaggregase activity in the absence of
Hsp70 andHsp40, we employed amutant subunit doping strat-
egy (26, 70). Here, subunits were mixed to generate heterohex-
amer ensembles according to the binomial distribution (Fig.
1B) (26, 70).Wehave previously demonstrated thatHsp104 and
Hsp104A503V assemble into dynamic hexamers that rapidly
exchange subunits, ensuring statistical incorporation of indi-
vidual subunits (Fig. 1B) (26, 62). By applying different hetero-
hexamer ensembles composed of Hsp104 and Hsp104A503V
subunits to reactivate disordered luciferase aggregates, we can
obtain ameasure of howmanyA503V subunits per hexamer are
required for disaggregase activity in the absence of Hsp70 (Fig.
1, B and C) (26, 29, 61, 62, 70).
We assembled different heterohexamer ensembles of
Hsp104A503V and Hsp104WT subunits (Fig. 1B) and assessed
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their luciferase reactivation activity (Fig. 1C). Incorporation of
Hsp104 subunits into Hsp104A503V hexamers caused a shallow
curvilinear decline in luciferase disaggregase activity consistent
with
4–5WT Hsp104 subunits being necessary to inactivate
the Hsp104A503V hexamer (Fig. 1C, compare blue markerswith
purple and light blue lines). If four WT subunits inactivate the
Hsp104A503V hexamer, then two A503V subunits are not
enough for activity (hence, we need three), and if five WT sub-
units inactivate theHsp104A503V hexamer, then a single A503V
subunit is insufficient for activity (hence, we need two). Thus,
2–3 Hsp104A503V subunits/hexamer are required to dissolve
disordered luciferase aggregates in the absence of Hsp70. Strik-
ingly, we previously demonstrated that two Hsp104 subunits
must be capable of interacting with Hsp70 to enable Hsp104-
mediated disaggregation of luciferase in the presence of Hsp70
(61). Hence, it is interesting that at least two A503V subunits
were needed to enable otherwiseWThexamers to disaggregate
luciferase in the absence of Hsp70 (Fig. 1C). This finding indi-
cates that A503V subunits might mimic the conformation of
Hsp70-activated, WT Hsp104 subunits. Moreover, this dose-
response curve (Fig. 1C) also suggests that Hsp104A503V sub-
units do not stimulate the activity of adjacentWTHsp104 sub-
units (26, 62). Thus, a single Hsp104A503V subunit is unable to
potentiate an otherwise WT hexamer.
Interestingly, however, none of the theoretical curves exactly
match the experimental data (Fig. 1C). Rather, the data fall
mostly between the curves for four or five WT subunits being
required to inhibit the activity of anHsp104A503V hexamer (Fig.
1C, compare blue markers with purple and light blue lines).
However, we could model the observed behavior more pre-
cisely if we imposed rules whereby a WT subunit represses the
activity of an adjacent A503V subunit by a factor of
0.3 and is
inactive if adjacent to another WT subunit (Fig. 1D, compare
blue markers with purple line; see “Experimental Procedures”).
Hsp104A503V Disaggregase Activity Is Diminished by Muta-
tions That Disrupt Substrate Binding to NBD Pore Loops—We
next examined how Hsp104A503V would respond to specific
defects in substrate binding. Residues Tyr-257 and Tyr-662 are
located in flexiblepore loops locatedwithineachNBDand face the
central channel through which substrate is translocated (Fig. 1A)
(37, 38, 42–44).Eachpore loop tyrosineengages substratedirectly,
andmutating these residues to alanine results in severely reduced
(Y257A) or abolished (Y662A) disaggregation activity (43, 44).
We introduced missense mutations Y257A, Y662A, or both in
combination with A503V, resulting in Hsp104Y257A/A503V,
Hsp104Y662A/A503V, and Hsp104Y257A/A503V/Y662A. First, we
measured the ATPase activity of these Hsp104 variants using
the more sensitive low salt conditions of Hattendorf and
Lindquist (52), which maximally stabilize Hsp104 hexamers.
Under these conditions, surprisingly, Hsp104A503V displays
only
18%higherATPase activity thanHsp104 (Fig. 2A). Thus,
enhanced ATPase activity of Hsp104A503V compared with
Hsp104 determined previously at physiological salt concentra-
tions may reflect slight variations in hexamer stability (62, 77,
78). Hsp104 displayed ATPase activity similar to that of
Hsp104Y257A and Hsp104Y662A, but Hsp104Y257A/Y662A ATPase
activity was significantly elevated (Fig. 2A). We had not observed
this increase previously at physiological salt concentrations
(26). Compared with Hsp104A503V, Hsp104Y257A/A503V and
Hsp104Y662A/A503V had very similar ATPase activity, whereas
Hsp104Y257A/A503V/Y662A was 
35% lower (Fig. 2A). Thus, the
double pore loop mutation had opposite effects on ATPase
activity in the wild type versus A503V background (Fig. 2A).
Nonetheless, all pore-loop variants displayed robust ATPase
activity under these conditions.
We next assessed the reactivation of luciferase trapped in
disordered aggregates in the absence ofHsp70 andHsp40 but in
the presence of ATP.Under these conditions, Hsp104A503Vwas

33-fold more active than Hsp104 (Fig. 2B). In the A503V
background, the pore loop mutations abolished this enhanced
activity and reduced refolding activity to a low level similar
to Hsp104 (Fig. 2B) (23). The effect of Y662A was slightly
greater than Y257A, but either mutation severely diminished
Hsp104A503V activity (Fig. 2B). Thus, Hsp104A503V disaggre-
gase activity is likely mediated via substrate interactions with
Tyr-257 and Tyr-662.
In the presence of 1:1 mixtures of ATP and ATPS, Hsp104
can disaggregate disordered aggregates in the absence of Hsp70
(26, 60, 61, 68). Under these conditions, Hsp104A503V displays
reduced luciferase reactivation activity compared with Hsp104
(Fig. 2C). This finding suggests that Hsp104A503V responds dif-
ferently fromHsp104 tomixtures ofATP andATPS,whichwe
explore further below. In these conditions, Hsp104Y257A and
Hsp104Y662A are devoid of luciferase reactivation activity. Like-
wise, all pore-loop variants bearing the A503V mutation
showed diminished luciferase reactivation activity (Fig. 2C).
Next, we studied Hsp104 disaggregase activity in the pres-
ence of Hsp72 (an Hsp70) and Hdj1 (an Hsp40). Here,
Hsp104A503V luciferase-refolding activity was 
2-fold lower
than that of Hsp104 (Fig. 2D). This result was surprising
because Hsp104A503V has increased luciferase reactivation
activity in the presence of Hsc70 and Hdj2 as well as Sse1, Ssa1,
and Ydj1 (62, 67). Thus, the identity of Hsp70 and Hsp40 chap-
erone partners canmodulate the activity ofHsp104A503V differ-
ently fromHsp104. For both Hsp104 and Hsp104A503V, Y257A
or Y662A greatly reduced activity (Fig. 2D). The Y257A muta-
tion greatly impaired activity in bothHsp104 andHsp104A503V,
whereas the Y662A or the Y257A/Y662A mutations abolish
FIGURE 1. Hsp104 hexamers must contain 2–3 A503V subunits for enhanced disaggregase activity in the absence of Hsp70. A, domain structure of
Hsp104. TheN-terminal domain (purple), NDB1 (olive green), MD (orange), NBD2 (blue), and the C-terminal domain (red) are shown. Hsp104mutations included
in this study and their functional effects are also shown.Mutations affecting substrate binding are shown inmustard, whereasmutations affectingATPbinding
and hydrolysis are shown in light blue. The potentiatingmutation A503V is shown in pink. B, theoretical Hsp104 heterohexamer ensembles containing 0–6WT
subunits as a function of the fraction of WT subunit present. C, Hsp104 was mixed in varying ratios with Hsp104A503V to create heterohexamer ensembles.
Luciferase disaggregation and reactivation activity was assessed in the absence of Hsp70 and Hsp40. Values represent means  S.E. (error bars) (n  3).
Theoretical curves are shown to illustrate the predicted result when 1–6 WT subunits are needed to inactivate the Hsp104A503V hexamer. D, the data plotted
in C are replotted. Theoretical curves are shown where adjacent pairs of A503V:A503V or A503V:WT subunits confer hexamer activity, whereas adjacent WT
subunits are inactive. Each adjacent A503V:A503V pair has an activity of 1/6. Adjacent A503V:WT pairs have a repressed activity (r), and the effects of various r
values are depicted.
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activity (Fig. 2D) (62). Thus, Tyr-257 and Tyr-662 play a crucial
role in Hsp104A503V disaggregase activity, indicating that
potentiated Hsp104 variants employ a mechanism of substrate
translocation similar to that of Hsp104.
To complement our in vitro studies, we utilized yeast models
of cytotoxic misfolding and aggregation of proteins involved in
neurodegenerative diseases, such as Parkinson disease andALS
(74, 75, 79). In Parkinson disease, -syn assembles into toxic
soluble oligomers and amyloid fibrils (80). In yeast, expression
of -syn from the galactose promoter induces cytoplasmic
aggregation and toxicity (79). In these experiments, we ex-
ploited a hsp104 yeast strain to avoid any potential interfer-
ence from endogenous Hsp104 (Fig. 3, A and B) (62). Deletion
or overexpression of Hsp104 does not affect -syn aggregation
or toxicity in yeast (62, 63, 67). Thus, we can be certain that any
rescue of toxicity by an Hsp104 variant in the hsp104 back-
ground is due to a gain of Hsp104 therapeutic function (62, 63,
67).We first established that differences in growthwere not due
to changes in the expression of -syn or Hsp104 variants via
immunoblotting (Fig. 3B). As expected, a vector control,
Hsp104, Hsp104Y257A, Hsp104Y662A, or Hsp104Y257A/Y662A did
not reduce -syn toxicity (Fig. 3A). By contrast, Hsp104A503V
strongly suppressed-syn toxicity (Fig. 3A) (35, 62, 63, 66). This
rescue was severely impaired by the Y257A mutation and
ablated by the Y662A or Y257A/Y662A mutations (Fig. 3A).
In ALS, the RNA-binding proteins with prion-like domains,
TDP-43 and FUS, mislocalize from the nucleus and form cyto-
plasmic aggregates in degenerating motor neurons (17, 18, 80).
In yeast, expression of FUS or TDP-43 from the galactose pro-
moter induces their cytoplasmic aggregation and toxicity (73–
75). Here too, we utilized ahsp104 yeast strain (Fig. 3,D–F), in
which either FUS or TDP-43 aggregates and is highly toxic (62,
73, 81). Hsp104A503V mitigated cytoplasmic FUS aggregation
and toxicity in yeast, whereas Hsp104 had no effect (Fig. 3C)
FIGURE 2.Hsp104A503Vdisaggregase activity is severely impairedby theY257Amutationandablatedby theY662Amutation.A, Hsp104mutants (0.25
Mmonomer)were incubated for 10minwithATP (1mM). Averageabsorbance fromanoenzymecontrol reactionwas subtracted fromrawabsorbancevalues.
The resulting absorbance values were normalized to the average absorbance yielded by Hsp104WT. Values represent means S.E. (error bars) (n 16–48). A
one-way analysis of variance with the post hoc Tukey’s multiple comparisons test (*, p 0.05; **, p 0.01) was performed. B, urea-denatured firefly luciferase
aggregates were incubated for 90 min at 25 °C with Hsp104 (1 M hexamer) plus ATP. Luciferase reactivation was then determined and normalized to
Hsp104WT disaggregase activity. Values represent means S.E. (n 6–90). C, reactions were performed as in B except that 1:1 mixtures of ATP and ATPS
replaced ATP. Values represent meansS.E. (n 6–84). D, reactions were performed as in B except that Hsp70 (1 M) and Hsp40 (1 M) were added. Values
represent means S.E. (n 6–84).
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(35, 62, 63, 66, 81). This rescue was abrogated by the Y257A
mutation (Fig. 3C). No other Hsp104 variant tested here
reduced FUS toxicity (Fig. 3C). Consistent with previous
reports (62, 63), we found that Hsp104A503V slightly reduced
FUS expression levels (Fig. 3D). However, Hsp104A503V was
also expressed at lower levels than the other Hsp104 variants
(Fig. 3D).
None of the pore loop mutants could suppress TDP-43 tox-
icity in yeast (Fig. 3E) (62, 73, 74). Only Hsp104A503V rescued
TDP-43 toxicity (Fig. 3E). Hsp104A503V very slightly reduced
TDP-43 expression level and was itself also expressed at lower
levels than Hsp104 (Fig. 3F). We conclude that the Hsp104
potentiation conferred by A503V is severely disrupted by the
Y257A mutation and ablated by the Y662A mutation.
Hsp104A503V Responds Differently from Hsp104 to Mix-
tures of ATP and ATPS—Unlike Hsp104, Hsp104A503V was
not stimulated in luciferase reactivation by a 1:1 ratio of ATP
to ATPS in the absence of Hsp70 (Fig. 2C). This finding sug-
gested that an altered pattern of ATP hydrolysis by
Hsp104A503V hexamers might contribute to potentiation. To
explore this idea further, we examined the effect of various
ratios of ATP and ATPS on Hsp104 and Hsp104A503V disag-
gregase activity. We kept the total adenine nucleotide con-
centration constant but varied the ATP/ATPS ratio. In Fig.
4A, we present the data normalized to WT Hsp104 maximal
activity to reveal the amplitude of the activity of the different
Hsp104 variants tested. In Fig. 4B, we present the data normal-
ized to the maximal activity of each individual Hsp104 variant
to reveal the optimal ATP/ATPS ratio. Hsp104 exhibited
maximal luciferase reactivation activity at 
40–50% ATPS
(Fig. 4, A and B, blue trace) (26, 35). By contrast, the dose
response of Hsp104A503V was left shifted toward lower levels of
ATPS (Fig. 4, A and B, compare blue and green traces). Thus,
Hsp104A503V exhibitedmaximal luciferase reactivation activity
at 
20–30% ATPS (Fig. 4, A and B, green trace) and was
sharply inhibited at ATPS concentrations that were optimal
for Hsp104 (Fig. 4, A and B). Utilization of ATPS in combina-
tion with ATP stimulates disaggregation of disordered aggre-
gates by Hsp104 via slowing ATP hydrolysis at subset of nucle-
otide-binding sites (26, 60). Thus, the heightened sensitivity of
Hsp104A503V to stimulation by lower proportions of ATPS
indicates that Hsp104A503V requires slowing of ATP hydrolysis
at fewer nucleotide-binding sites than Hsp104.
ATP hydrolysis can be specifically slowed at NBD1 or NBD2
by mutating their conserved Walker A motif, which harbors a
lysine residue that directly contacts the phosphates ofATP (21).
Mutating the conserved lysine of the Walker A motif to threo-
nine impairs ATP binding at that site (21, 49, 51). Alternatively,
ATP hydrolysis can be slowed at NBD1 or NBD2 by mutating
their conserved sensor-1 motif, which harbors a threonine or
asparagine that interacts with the -phosphate of ATP (21, 52).
Mutating the conserved threonine or asparagine of the sensor-1
FIGURE 3. Hsp104A503V-mediated rescue of yeast proteinopathy models is severely impaired by the Y257A mutation and ablated by the Y662A
mutation. hsp104 yeasts integrated with genes encoding -syn (A), FUS (C), or TDP-43 (E) were transformed with the indicated Hsp104 variants or empty
vector control. Strains were serially diluted 5-fold and spotted on glucose (off) or galactose (on)medium. B,D, and F, strains from A, C, and E, respectively, were
induced, lysed, and immunoblotted. 3-Phosphoglycerate kinase (PGK) was used as a loading control. Results shown are representative of at least three
independent trials.
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motif to alanine does not affect ATP binding but inhibits ATP
hydrolysis at that site (21, 52). Slowing ATPase activity specifi-
cally atNBD2withK620T (WalkerA) orN728A (sensor-1), but
not NBD1 with K218T (Walker A) or T317A (sensor-1) (Fig.
1A), enables disaggregation of disordered aggregates byHsp104
in the presence of ATP and absence of Hsp70 (Fig. 4, A and B)
(data not shown) (60).
Next, we assessed how the disaggregase activity of the sen-
sor-1 variants, Hsp104T317A and Hsp104N728A, was affected by
increasing proportions of ATPS. Hsp104T317A showed no dis-
aggregase activity in the presence of just ATP (Fig. 4, A and B,
black trace) (60). Surprisingly, however, mixtures of ATP and
ATPS stimulated Hsp104T317A disaggregase activity (Fig. 4, A
and B, black trace). The dose response of Hsp104T317A was
similar to that of Hsp104 except slightly right-shifted toward
higher ATPS levels (Fig. 4, A and B, compare black and blue
traces). Maximal Hsp104T317A disaggregase activity was
observed at 
50% ATPS, and at higher ATPS concentra-
tions, Hsp104T317A disaggregase activity declined (Fig. 4,A and
B, compare black and blue traces). These findings indicate that,
surprisingly, slowing ATP hydrolysis at NBD2 even when it is
the only intact NBD can stimulateHsp104 disaggregase activity
against disordered aggregates in the absence of Hsp70.
In striking contrast, Hsp104N728A maximally reactivated
luciferase in the presence of ATP but was sharply inhibited by
increasing fractions of ATPS (Fig. 4, A and B, red trace) (60).
This finding suggests that slowing ATP hydrolysis at NBD1
when it is the only intact NBD strongly inhibits disaggregase
activity against disordered aggregates in the absence of Hsp70.
Hsp104T317A/A503V displayed a response to ATPS similar to
that of Hsp104A503V except that it was slightly right-shifted
toward higher ATPS levels (Fig. 4, A and B, compare orange
and green traces). Indeed, Hsp104T317A/A503V was less inhibited
than Hsp104A503V by ATPS at concentrations higher than
30% (Fig. 4, A and B, compare orange and green traces). Maxi-
mal Hsp104T317A/A503V luciferase reactivation activity was
FIGURE4.Hsp104A503V requiresa lowerproportionofATPS formaximaldisaggregaseactivity in theabsenceofHsp70comparedwithHsp104.A and
B, urea-denatured firefly luciferase aggregates were incubated for 90 min at 25 °C with the indicated Hsp104 variant (1 M hexamer) in the presence of the
indicated amounts of ATP andATPS (total nucleotide concentrationwas kept constant). Values representmeans S.E. (error bars) (n 4–5).A, all data points
were normalized to the maximum refolding activity of WT Hsp104. B, all data points were normalized to the maximum refolding activity for a given Hsp104
mutant.
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observed at
30% ATPS (Fig. 4, A and B, orange trace). Thus,
the T317A mutation renders Hsp104 and Hsp104A503V less
sensitive to inhibition by higher ATPS concentrations.
Remarkably, Hsp104A503V/N728A was even more sensitive to
inhibition by ATPS than Hsp104N728A (Fig. 4, A and B, com-
pare purple and red traces). Hsp104A503V/N728A maximally
reactivates luciferase in the presence of ATP but is completely
inhibited by as little as 10% ATPS (Fig. 4, A and B, purple
trace). Collectively, these observations indicate that altered
ATP hydrolysis patterns might contribute to the enhanced
activity of Hsp104A503V. They also illustrate the startlingmech-
anistic plasticity of the Hsp104 hexamer for disaggregating dis-
ordered aggregates (26).
PotentiatedHsp104A503VActivity CanTolerate Sensor-1Mu-
tations in NBD1 or NBD2—Hsp104A503V exhibits increased
ATPase activity at physiological salt concentrations (62, 77, 78)
and is more sensitive to suramin, a small molecule inhibitor of
Hsp104 ATPase activity (68). Furthermore, we show here that
Hsp104A503V responds differently to ATPS (Fig. 4, A and B).
Moreover, Hsp104A503V ATPase activity is inhibited and not
stimulated by polylysine, unlikeHsp104 (78). These results sug-
gest that altered ATPase activity is a key element enabling the
potentiated activity of Hsp104A503V. Thus, we next delineated
the requirements for ATPase activity at NBD1 and NBD2 for
potentiated Hsp104A503V activity. To do so, we introduced the
AAA sensor-1 mutations T317A and N728A (Fig. 1A) (52).
We also introduced mutations in the Walker A and Walker B
motifs of both NBDs; Hsp104K218T/K620T was unable to bind
nucleotide, whereas Hsp104E285Q/E687Q bound nucleotide but
was unable to hydrolyze it (Fig. 1A) (82).
In the WT Hsp104 background, both sensor-1 mutants dis-
played significantly reduced ATPase activity, whereas the dou-
bleWalker A andWalker B mutants showed almost no activity
(Fig. 5A) (49, 51, 52, 82). Likewise, in the A503V background,
the double Walker A or double Walker B mutants eliminated
ATPase activity (Fig. 5A). The NBD1 sensor-1 mutant dis-
played reduced ATPase activity in the A503V background (Fig.
5A; compared with Hsp104A503V). Indeed, the ATPase activity
of Hsp104T317A/A503V was reduced by 
32% compared with
Hsp104A503V, and this reduction was statistically significant (Fig.
FIGURE 5.A potentiated Hsp104 variant can overcome deficits in ATP hydrolysis at NBD1 or NBD2 in vitro. A, Hsp104A503V mutants (0.25M monomer)
were incubated for 10minwith ATP (1mM). Average absorbance fromano enzyme control reactionwas subtracted from raw absorbance values. The resulting
absorbancevalueswerenormalized to theaverageabsorbance yieldedbyHsp104WT. Values representmeanS.E. (error bars) (n16–48). Aone-wayanalysis
of variance with the post hoc Tukey’s multiple comparisons test (*, p 0.05; **, p 0.01; ***, p 0.001) was performed. B, urea-denatured firefly luciferase
aggregates were incubated for 90 min at 25 °C with Hsp104 (1 M hexamer) plus ATP. Luciferase reactivation was then determined and normalized to
Hsp104WT disaggregase activity. Values represent mean  S.E. (n  6–78). C, reactions were performed as in B except that 1:1 mixtures of ATP and ATPS
replaced ATP. Values represent mean S.E. (n 6–72). D, reactions were performed as in B except that Hsp70 (1 M) and Hsp40 (1 M) were added. Values
represent mean S.E. (n 6–72).
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5A). This reduction was similar to the effect of T317A in WT
Hsp104 (Fig. 5A). By contrast, the activity ofHsp104A503V/N728Awas
reduced by only 
18% compared with Hsp104A503V, and this
reduction was not statistically significant (Fig. 5A). This reduc-
tion was not as large as the statistically significant
33% reduc-
tion of ATPase activity caused by N728A in the WT Hsp104
background (Fig. 5A). However, we note that the ATPase activ-
ity of Hsp104T317A/A503V and Hsp104A503V/N728A were not sig-
nificantly different (Fig. 5A). Collectively, these findings begin
to suggest that allosteric communication between NBD1 and
NBD2 may be altered in Hsp104A503V (52, 78). Indeed, NBD1
appears to make a larger contribution to the ATPase activity in
Hsp104A503V than in Hsp104 (Fig. 5A). These observations
indicate that NBD1 may retain high ATPase activity when
NBD2 is bound with ATP in the A503V background. By con-
trast, in Hsp104, NBD1 ATPase activity is low when ATP is
bound by NBD2 (52).
Next, we determined the luciferase disaggregase activity of
theseHsp104ATPase variants in the presence ofATPbut in the
absence of Hsp70. In the presence of ATP alone, the double
Walker A or Walker B mutants displayed insignificant lucifer-
ase reactivation activity in both theWT and A503V backgrounds
(Fig. 5B). As expected,Hsp104 andHsp104T317Awere also inactive
in this setting (Fig. 5B). Hsp104A503V and Hsp104T317A/A503V dis-
played robust disaggregase activity under these conditions (Fig.
5B). Thus, reducing ATPase activity at NBD1 did not affect the
ability of Hsp104A503V to disaggregate disordered aggregates.
Hsp104N728A reactivated luciferase trapped in urea-denatured
aggregates 
11-fold more effectively than Hsp104A503V (Fig.
5B). Although Hsp104N728A has previously been shown to be
active under these conditions (60), wewere surprised that it was
considerably more active than Hsp104A503V. Remarkably,
Hsp104A503V/N728A displayed even greater luciferase reactiva-
tion activity (Fig. 5B). Thus, slowing ATP hydrolysis at NBD2
substantially enhances the ability of Hsp104 and Hsp104A503V
to disaggregate disordered aggregates in the presence of ATP
and absence of Hsp70 (60).
In the presence of a 1:1 mixture of ATP/ATPS, the double
Walker A or Walker B mutants were unable to elicit any lucif-
erase reactivation in both the WT and A503V backgrounds
(Fig. 5C). TheT317Amutation had little effect onHsp104 activ-
ity under these conditions but slightly stimulated Hsp104A503V ac-
tivity (Figs. 4 and 5C). By contrast, the N728A mutation
strongly inhibited Hsp104 and Hsp104A503V activity at 1:1
ATP/ATPS (Figs. 4 and 5C). Thus, slowing ATP hydrolysis at
NBD2 increases the sensitivity of Hsp104 and Hsp104A503V to
inhibition by ATPS.
In the presence of Hsp70 (Hsp72) and Hsp40 (Hdj1), the
doubleWalker A orWalker Bmutants were inactive in theWT
and A503V background (Fig. 5D). Surprisingly, under these
conditions, Hsp104T317A activity was very similar to that of
Hsp104, whereas Hsp104N728A exhibited elevated activity (Fig.
5D). Similar results were observed in the A503V background.
Thus, Hsp104T317A/A503V exhibited activity similar to that of
Hsp104A503V, whereas Hsp104A503V N728A exhibited elevated
activity and was the most active variant in this assay (Fig. 5D).
Under these conditions, slowing ATP hydrolysis at NBD2
increased Hsp104 and Hsp104A503V luciferase reactivation
activity in the presence of Hsp70 and Hsp40, whereas slowing
ATP hydrolysis at NBD1 had little effect on activity (Fig. 5D). A
summary of the various activities of the Hsp104 variants tested
here is presented in Table 1.
Next, we assessed whether these Hsp104 ATPase variants
could rescue toxicity of -syn, FUS, or TDP-43 in yeast (Fig. 6,
A–F). In the context of WT Hsp104, none of the ATPase vari-
ants affected the expression or toxicity of-syn (Fig. 6,A andB),
FUS (Fig. 6,C andD), or TDP-43 (Fig. 6, E and F) in yeast. Thus,
despite having enhanced ability to reactivate luciferase aggre-
gates in vitro (Fig. 5,B andD), Hsp104N728Awas inactive against
the neurodegenerative disease proteins in vivo (Fig. 6,A,C, and
E). Previously, we had established that an important property of
potentiated Hsp104 variants bearing mutations in the MD was
increased disaggregase activity against disordered aggregates in
the absence of Hsp70 andHsp40 (62, 63, 65–67). However, our
findings with Hsp104N728A (Figs. 5 (B and D) and 6 (A, C, and
E)) indicate that this activity is not sufficient for potentiated
activity in vivo. Despite having enhanced ability to disaggregate
disordered aggregates in vitro (Fig. 5, B andD), Hsp104N728A is
unable to resolve amyloid conformers (24, 33). By contrast,
Hsp104A503V has enhanced activity against both amyloid and
non-amyloid aggregates in vitro (62, 63, 67). Thus, enhanced
disaggregase activity against amyloid is a better predictor of
potentiated activity in vivo.
Hsp104A503V strongly rescued the toxicity of -syn (Fig. 6A),
FUS (Fig. 6C), and TDP-43 (Fig. 6E) in yeast (62, 63, 67). This
potentiated activity was ablated by either the double Walker A
or Walker B mutation (Fig. 6, A, C, E). Remarkably, however,
both Hsp104T317A/A503V and Hsp104A503V/N728A retained
potentiated activity in vivo and rescued toxicity of -syn (Fig.
6A), FUS (Fig. 6C), and TDP-43 (Fig. 6E). Hsp104T317A/A503V
rescued the toxicity of all three disease proteins just as well as
Hsp104A503V (Fig. 6, A, C, and E), whereas Hsp104A503V/N728A
rescued-syn and FUS toxicity just aswell asHsp104A503V (Fig.
6, A and C) but had reduced ability to rescue TDP-43 toxicity
(Fig. 6E). Rescue of -syn toxicity was observed without any
effect on -syn expression level (Fig. 6B). By contrast, rescue of
FUS toxicity by Hsp104A503V and Hsp104T317A/A503V was
accompanied by a reduction in FUS expression level (Fig. 6D).
However, Hsp104A503V/N728A rescued FUS toxicity without
affecting the FUS expression level (Fig. 6D). Hence, the reduc-
tion of FUS expression is not required to rescue toxicity. For
TDP-43, Hsp104A503V and Hsp104T317A/A503V also modestly
reduced TDP-43 expression level, whereas Hsp104A503V/N728A
did not (Fig. 6F). Therefore, the reduction in TDP-43 expres-
sion is also not required for rescue of toxicity. These findings
suggest that the potentiated activity of Hsp104A503V in yeast is
largely unaffected by reducing ATPase activity at NBD1 or
NBD2.
Discussion
Several missense mutations at specific but disparate posi-
tions in the MD or the small domain of NBD1 result in poten-
tiated Hsp104 variants, able to dissolve protein aggregates
implicated in neurodegenerative diseases (35, 62–67). These
mutations probably disrupt a fragilely constrained, autoin-
hibited state of Hsp104 (67). However, the exact molecular
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basis of Hsp104 potentiation remains unclear. Here, we have
dissected mechanistic aspects of a potentiated Hsp104 variant,
Hsp104A503V (35, 62–67). We have revealed how many sub-
units within the Hsp104 hexamer must bear a potentiating
mutation to yield enhanced activity. We have also determined
the ATPase and substrate-binding modalities that underpin
potentiation in vitro and in vivo.
Using a mutant subunit doping strategy (26, 35, 61, 70), we
have established that 2–3 subunits of an otherwise WT hex-
amer must bear A503V mutations to elicit enhanced disaggre-
gase activity in the absence of Hsp70. Intriguingly, at least two
Hsp104 subunits must interact with Hsp70 to enable disaggre-
gation of disordered aggregates (61). We suggest that A503V
subunits mimic the conformation ofWTHsp104 subunits that
have been activated by Hsp70 binding. Hsp70 and Hsp40 are
often sequestered in disease-associated aggregates, which
might inhibit their function (83, 84). Thus, the ability of
Hsp104A503V to operate without Hsp70 and Hsp40 probably
contributes to enhanced activity against disease-associated
substrates in yeast (62, 63, 66, 67). Nonetheless, the NBD2 sen-
sor-1 variant, Hsp104N728A, can disaggregate disordered aggre-
gates (but not amyloid) in vitro in the absence of Hsp70 (24, 33,
60), but, in contrast to Hsp104A503V, Hsp104N728A is unable to
rescue -syn, FUS, and TDP-43 toxicity in yeast. It is possible
that Hsp104N728A ATPase activity is too low to process certain
aggregated substrates in vivo or that there are elements inhib-
iting activity in vivo that we do not reconstitute in our in vitro
experiments. Regardless, these findings suggest that separation
from Hsp70 and Hsp40 is not the only important determinant
in Hsp104 potentiation.
We show that the Hsp104 potentiation conferred by A503V
is severely impaired by mutating conserved substrate-binding
tyrosines to alanine. In WT Hsp104, mutating Tyr-257 and
Tyr-662 to alanine results in severely reduced (Y257A) or abol-
ished (Y662A) disaggregation activity (43, 44). This was also the
case for Hsp104A503V. Hsp104Y257A/A503V retained slightly
more activity thanHsp104A503V/Y662A in all conditions tested in
vitro. However, the Y257A pore-loop variants are unable to
rescue yeast proteinopathy models. These results suggest that
Hsp104A503V recognizes and translocates substrates via direct
contact with conserved Tyr-257 and Tyr-662 pore-loop resi-
dues in a manner similar to Hsp104.
In the absence of Hsp70, Hsp104A503V disaggregase activity
against disordered aggregates responded differently from
Hsp104 to mixtures of ATP and ATPS. Indeed, optimal
Hsp104A503V disaggregase activity was observed at
4:1 ATP/
ATPS compared with 
1:1 for Hsp104. Mixtures of ATPS
and ATP stimulate disaggregation of disordered aggregates
by Hsp104 via decelerating ATP hydrolysis at a subset of
nucleotide-binding sites (26, 60). Thus, stimulation of disag-
gregase activity by lower fractions of ATPS indicates that
Hsp104A503V requires decelerated ATPase activity at fewer
nucleotide-binding sites. This finding suggests that an altered
pattern of ATP hydrolysis underlies Hsp104 potentiation.
TABLE 1
Summary of Hsp104 variants and their ATPase and luciferase reactivation activities under the conditions tested in this paper
Numbers for partial or increased activities are noted. Numbers in blue represent a decrease in activity with respect to Hsp104WT, whereas numbers in red represent
increased activity.
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FIGURE 6. ATPase activity at NBD1 or NBD2 in Hsp104A503V is sufficient to sustain potentiation in yeast proteinopathy models. hsp104 yeasts
integratedwithgenes encoding-syn (A), FUS (C), or TDP-43 (E)were transformedwith the indicatedHsp104mutants or control. Strainswere serially diluted
5-fold and spotted on glucose (off) or galactose (on) medium. B, D, and F, strains from A, C, and E, respectively, were induced for 5 or 8 h, lysed, and
immunoblotted. 3-Phosphoglycerate kinase was used as a loading control. Results shown are representative of at least three independent trials.
FIGURE 7. Summary of keymechanistic insights into Hsp104 potentiation. PD, Parkinson disease.
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Analysis of various ATPase-defective mutants revealed that
enhanced Hsp104A503V activity requires ATPase activity be-
cause double Walker A or Walker B mutants were ATPase-
dead and non-functional in all assays studied here (62). Interest-
ingly, the sensor-1 mutants, T317A and N728A (52), revealed
alterations in allosteric signaling between NBD1 and NBD2 in
Hsp104A503V. In the WT background, both T317A and N728A
significantly reduce Hsp104 ATPase activity (52). Indeed, based on
this observation, it is suggested thatHsp104NBD1ATPase activity is
low when ATP is bound by NBD2 (52). However, in Hsp104A503V,
only the T317A mutation significantly impairs ATPase activity.
Indeed,N728Ahas little effect onHsp104A503VATPase activity. It
should be noted that despite these differences, the ATPase activi-
tiesofHsp104T317A/A503VandHsp104A503V/N728Awerenot signif-
icantly different. Nonetheless, collectively, our findings begin to
suggest thatNBD1makes a larger contribution toATPase activity
inHsp104A503V than inHsp104.The essentially unalteredATPase
activity of Hsp104A503V/N728A may indicate that NBD1 retains
highATPaseactivitywhenNBD2isboundwithATPin theA503V
background.We suggest that this alteration in allosteric signaling
between NBD1 and NBD2 probably plays an important role in
Hsp104 potentiation.
Remarkably, both Hsp104T317A/A503V and Hsp104A503V/N728A
retain potentiated activity in vivo and in vitro. Thus, the poten-
tiated activity of Hsp104A503V is largely unaffected by reducing
ATPase activity at NBD1 or NBD2. Hsp104A503V/N728A dis-
played slightly reduced ability to rescue TDP-43 toxicity in
yeast but still provided significant rescue. By contrast, the
equivalent sensor-1 mutations in WT Hsp104 greatly reduce
activity in yeast with respect to thermotolerance and prion
propagation (52, 85). Thus, Hsp104A503V displays a more
robust activity with an operational plasticity that is unper-
turbed by mutations that greatly reduce activity of Hsp104 in
vivo (52, 62, 85). A summary of the key findings of our study is
presented in Fig. 7.
These insights into the molecular underpinnings of Hsp104
potentiation help to lay foundations to further develop next
generation Hsp104 variants with ameliorated therapeutic util-
ity for neurodegenerative diseases. For example, our findings
hint that the specificity of potentiated Hsp104 variants
might be sharpened by more subtle alterations to the NBD1
pore-loop or by more severely reducing NBD2 ATPase activ-
ity. Potentiated Hsp104 variants with enhanced substrate or
conformer selectivity might exhibit reduced off-target
effects and consequently display increased therapeutic effi-
cacy and safety (66).
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